

Pandemic Solutions

DigiChip™ SARS-CoV-2 Assay

Ultra-Sensitive SARS-CoV-2 Detection Assay

The DigiChip™ SARS-CoV-2 Assay, performed on the QuarkBio's NextAmp™ Analysis System with proprietary DigiChip™ technology, is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swabs collected from individuals suspected of COVID-19. The test has been approved by Taiwan FDA for EUA in authorized laboratories.



For use under an EUA only (TFDA)
防疫專案核准製造第1096818270號

Key Features

ULTRA-SENSITIVE

3x more sensitive than conventional qPCR with high accuracy, eliminating false negatives

HIGH SPECIFICITY

Design to distinguish COVID-19 from other similar respiratory pathogens, proven by both in vitro and in silico analyses

EFFICIENT & COST-EFFECTIVE

More affordable and easier to operate than ddPCR, but with comparable performance

FAST RESULTS

Less than 90-min turn-around time, providing test results in time for urgent cases

Specifications

Properties	Specifications
Input Analyte Type	Nucleic acids (viral RNA)
Target(s) of Detection	SARS-CoV-2 nucleocapsid protein gene N1
Limit of Detection	1,000 copies/mL
Sensitivity	100%
Specificity	100%
Accuracy	100%
Internal Control	Human RNase P gene
Hands-on Time	cDNA Synthesis : 10 min DigiChip™ Preparation: 15 min
Total Operation Time (from input analyte)	150 min Reverse Transcription: 60 min DigiChip™ Analysis: 90 min
Compatible Instrument	Q Station™ CV Dx
Specimen Type(s)	Nasopharyngeal swabs

Ordering Information

Reference No.	Product Name	Package Size
CV-R1	DigiChip™ SARS-CoV-2 Assay Kit	24 Assays
CV Dx	Q Station™ CV Dx	1 Set

For more information, please contact: info@quarkbiosciences.com